How much to invest in glycemic control of a patient with diabetes mellitus type 2? A constant dilemma for the Brazilian Public Health System (SUS)

Abstract

Diabetes mellitus type 2 (DM2) affects millions of people worldwide and causes several complications for the patient, consuming large sums of financial resources from the health services. This study aims to estimate the financial investment of DM2 treatment for glycemic control of the patient, from the point of view of the municipal Public Health System (SUS). The Delphi technique was used to validate the opinion of a team of judges, specialists in DM2, and health service managers, on the investment necessary for glycemic control of patients with DM2 through the application of questionnaires. In order for the patient to achieve glycated hemoglobin (A1c) < 7%, an investment of US$ 2,419.06 (value/patient/year) is necessary. As the value of A1c increases, investment is reduced. This result reveals the intention to allocate resources for the prevention of DM2 and its complications.

Glycemic control and associated factors in patients with type 1 diabetes mellitus in primary care in Southeastern Brazil

“…Results of data similarly reported in a multicenter, T1DM study, conducted between 2008 and 2010 in 20 Brazilian cities (Braga de Souza et al, 2015). A recent study done in Brazil reported that for the patient to achieve normoglycemia or euglycemia Hb1Ac levels seven or less percent (≤7.0%), an investment of US$ 2,419.06 (value/patient/year) is necessary and as the value of Hb1Ac decreases, costs are reduced (Gonçalves et al, 2019).…”